Thalidomide-NH-C6-NH2 is a specialized synthetic intermediate derived from thalidomide, primarily used in medicinal chemistry and chemical biology research. This modified compound features an aminohexyl linker (NH-C6-NH2) attached to the thalidomide core, enabling conjugation to other molecules such as antibodies, peptides, or PROTAC warheads for targeted drug delivery and protein degradation studies. It retains key properties of thalidomide, including cereblon (CRBN) binding for E3 ligase recruitment, immunomodulation, and anti-angiogenic effects, making it valuable for developing therapies against cancers (e.g., multiple myeloma), autoimmune diseases, and inflammatory conditions like leprosy-associated complications. Due to thalidomide's teratogenic risks, handling requires strict safety protocols, and it is not intended for direct clinical use but as a research reagent.